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Abstract
Background: Power Doppler ultrasound (PDUS) is increasingly used to assess synovitis in Rheumatoid Arthritis (RA). Prior
studies have shown correlations between PDUS scores and vessel counts, but relationships with T cell immunopathology
have not been described.
Methodology/Principal Findings: PBMC were isolated from healthy controls (HC) or RA patients and stimulated ex vivo with
PMA and ionomycin for 3 hours in the presence of Golgistop. Paired synovial fluid (SF) or synovial tissue (ST) were analysed
where available. Intracellular expression of IL-17, IFNc, and TNFa by CD4+ T cells was determined by flow cytometry.
Synovial blood flow was evaluated by PDUS signal at the knees, wrists and metacarpophalangeal joints of RA patients.
Serum, SF and fibroblast culture supernatant levels of vascular endothelial growth factor-A (VEGF-A) were measured by
ELISA. The frequency of IL17+IFNc-CD4+ T cells (Th17 cells) was significantly elevated in peripheral blood (PB) from RA
patients vs. HC (median (IQR) 0.5 (0.28–1.59)% vs. 0.32 (0.21–0.54)%, p=0.005). Th17 cells were further enriched (mean 6.6-
fold increase) in RA SF relative to RA PB. Patients with active disease had a higher percentage of IL-17+ T cells in ST than
patients in remission, suggesting a possible role for Th17 cells in active synovitis in RA. Indeed, the percentage of Th17 cells,
but not Th1, in SF positively correlated with CRP (r=0.51, p=0.04) and local PDUS-defined synovitis (r=0.61, p=0.002).
Furthermore, patients with high levels of IL-17+CD4+ T cells in SF had increased levels of the angiogenic factor VEGF-A in SF.
Finally, IL-17, but not IFNc, increased VEGF-A production by RA synovial fibroblasts in vitro.
Conclusions/Significance: Our data demonstrate a link between the presence of pro-inflammatory Th17 cells in SF and local
PDUS scores, and offer a novel immunological explanation for the observation that rapid joint damage progression occurs
in patients with persistent positive PDUS signal.
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Introduction
The pathogenesis of Rheumatoid Arthritis (RA) is complex and
involves multiple cells and inflammatory mediators, including
monocytes/macrophages, fibroblasts, B cells and T cells [1]. A
large body of literature, in both animal models of experimental
arthritis and human disease, demonstrates the critical contribution
of pro-inflammatory CD4+ T helper cell subsets to pathogenesis,
with particular roles for their signature cytokines IFNc (produced
by Th1 cells), IL-17A (produced by Th17 cells) and TNFa
(produced by both Th1 and Th17 cells, as well as monocytes/
macrophages) (reviewed in [2]).
Multiple animal models have demonstrated key roles of IL-17A
(henceforth called IL-17) and Th17 cells in the immunopathology
and joint damage of arthritis (reviewed in [3]). Further evidence for
the role of IL-17 in RA is provided by its biological properties in vitro
and in vivo, as it induces monocyte- and fibroblast-derived pro-
inflammatory cytokines(TNFa, IL-1b, IL-8), mediators of bone and
cartilage damage such as matrix metalloproteinases and RANK-
ligand (RANKL) [4,5,6], neutrophil and monocyte recruitment
[7,8], and osteoclastogenesis [9]. Bone and synovial explants from
RA joints exhibit increased production of functional IL-17
compared to OA joints [10], and IL-17+ CD4+ T cells can be
found in RA synovial tissue [11,12]. In early RA the cytokine profile
ofsynovialfluid(SF) is dominatedbythe presenceofIL-17 aswell as
Th2 cytokines [13]. Significantly, recent clinical trials with IL-17
antagonists in established RA show up to 42% ACR50 responses
with short duration therapy [14], providing the first direct evidence
in humans of a pathological role of IL-17 in RA, and indicating that
blockade of IL-17 in humans may be a valid therapeutic approach.
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to assess disease severity including elevated erythrocyte sedimen-
tation rate (ESR), C-reactive protein (CRP), swollen/tender joint
count at onset, rheumatoid factor, antibodies to citrullinated
proteins, extra-articular features or erosions at presentation
(reviewed in [15]). Imaging techniques, in particular power
Doppler ultrasound (PDUS), are increasingly being used as
imaging biomarkers of RA synovial inflammation. PDUS
measures the amplitude of flow signals within blood vessels with
high sensitivity [16]. Persistent positive PDUS signal in RA joints
predicts development of erosions in both early and established
disease [17,18]. Furthermore, PDUS scores reflect changes in
disease activity in patients treated with TNFa antagonists, and
patients with reduced PDUS scores following therapy have
reduced joint damage progression [19,20]. However, no data are
available that provide a link between PDUS scores and T cell-
mediated immunopathology in RA.
This study investigated the presence of Th1, Th17, IL-17+
IFNc+ and TNFa producing CD4+ T cells in PB, SF and ST from
RA patients and related these data to PDUS scores of either single
or multiple joints. Our data show that the frequency of IL-17+
IFNc-CD4+ T cells (Th17), but not IFNc+IL-17- CD4+ T cells
(Th1) or TNFa producing CD4+ T cells, in RA SF positively
correlates with systemic inflammation and local PDUS scores.
Patients with higher levels of SF IL-17+ CD4+ T cells also show
increased levels of the angiogenic factor VEGF-A in SF. In
addition, IL-17 and TNFa, but not IFNc, increase VEGF-A
production by RA synovial fibroblasts in vitro. In contrast, whilst
the percentage of Th17 cells is increased in the blood of RA
patients versus healthy controls, this is not correlated with clinical
parameters of disease or PDUS.
Methods
Objectives
This study aimed to compare frequencies of Th17, Th1, IL-17+
IFNc+ and TNFa+ CD4+ T cells in PB from RA patients and
healthy controls, and to assess if the relative proportions of these
cells were increased in either RA SF or ST. Furthermore, we
aimed to determine correlations between frequencies of these cells
in PB or SF, and synovitis as defined by PDUS score.
Participants
PB was obtained from patients with established RA according to
the 1987 American College of Rheumatology criteria [21]
attending for follow-up at Guy’s & St Thomas’ Rheumatology
Department. Healthy controls were recruited from hospital/
university students and members of staff. Patients with active
arthritis of one or more knees also had SF aspiration following
ultrasound of the knee joint. ST was obtained from six patients
with RA from the knee or elbow joint during arthroscopy. Age,
disease duration, medication, presence or absence of IgM
rheumatoid factor or erosions was obtained from review of the
medical notes. Disease activity was assessed by DAS28 on the day
of sample collection. ESR and CRP were determined on the day
of sample collection in the clinical laboratory.
Cell culture
PB and SF mononuclear cells (PBMC and SFMC, respectively)
were isolated by density gradient centrifugation using Lympho-
prep (PAA Laboratories, Pasching, Austria) and used immediately.
ST samples from the knee or elbow joint were digested using
10 mg/ml collagenase (Sigma-Aldrich, St Louis, USA) in RPMI
1640 (Invitrogen, Paisley, UK) at 37uC for one hour. PBMC,
SFMC or ST cells were cultured for 3 hours at a concentration of
1610
6/ml in RPMI 1640 medium supplemented with 1%
penicillin/streptomycin, 1% glutamine, and 10% heat-inactivated
FCS (all PAA). Cultures were stimulated with PMA (50 ng/ml;
Sigma-Aldrich) and ionomycin (750 ng/ml; Sigma-Aldrich) with
GolgiStop (according to manufacturer’s instructions (Becton
Dickinson, Franklin Lakes, USA) to encourage accumulation of
cytokines intracellularly.
Fibroblasts were cultured from RA ST obtained at the time of
arthroplasty until confluent in RPMI 1640 supplemented with 1%
penicillin/streptomycin, 1% glutamine, 10% FCS, 0.81X MEM
Non-essential amino acids, and 0.81 mM Sodium Orthopyruvate
(all Sigma-Aldrich). Once confluent, cells were trypsinized
(Trypsin-EDTA, Sigma-Aldrich) and seeded into culture plates.
Cells were harvested after five to seven passages for addition of
recombinant IL-17, TNFa, or IFNc (R&D Systems, Minneapolis,
USA) at the indicated concentrations.
Flow Cytometry
Cells were fixed in 2% paraformaldehyde (Merck) prior to
permeabilisation with Saponin 0.5% (Sigma-Aldrich) and staining
for 30 minutes at 4uC with anti-CD3-PE/Cy7 (Biolegend, San
Diego, USA), anti-CD4-PerCP/Cy5.5 (BD), anti-IFNc-FITC,
anti-TNFa-APC (both eBiosciences, San Diego, USA), and anti-
IL-17-PE (Biolegend) or the appropriate isotype controls. Cells
were acquired on a FACSCanto or FACSCalibur (BD) using bead
compensation and analysed using FlowJo (Treestar Inc, Ashland,
USA). Live cells were gated using forward and side scatter profiles;
T cells were identified by CD3 expression. T helper cell (CD4+ T
cell) subsets were defined as follows: Th17 cells were
CD3+CD4+IL-17+IFNc- and Th1 cells were CD3+CD4+IFN-
c+IL-17-.
ELISA
Serum, SF and fibroblast culture supernatants were stored at
280uC prior to analysis. VEGF-A and IL-6 specific ELISA (R&D
Systems) was performed according to the manufacturer’s instruc-
tions. Detection limit of the assay was 31.25 pg/ml for VEGF-A
and 20 pg/ml for IL-6.
PDUS image acquisition and analysis
Ultrasound (US) scans were performed within 2 hours of clinical
assessment in a darkened room using a Logiq 9 (GE Healthcare,
Buckinghamshire, UK) with a matrix array transducer (5–12
MHz). Synovial blood flow was evaluated by PDUS at the
metacarpophalangeal (MCP) joints and both wrists (24 RA
patients) and knee joints (20 patients, 22 knees) in longitudinal
and transverse views. For the knee joint, longitudinal and
transverse images were recorded of the suprapatellar pouch and
the lateral and medial patella recesses. The ultrasonographer was
blinded to clinical data at the time of the ultrasound examination,
and ultrasound images were anonymised prior to scoring. Pulse
repetition frequency was adjusted to the lowest permissible value
to maximize sensitivity, with the gain set at the point where
cortical PDUS signals disappeared. PDUS signals as a percentage
of synovial tissue were graded on a semi-quantitative scale from 0
to 3 (where 0 = no synovial flow; 1 = up to 25% synovial tissue
signal; 2 25–50% signal; 3 .50% signal). Scores for the three areas
of a single knee joint were used to calculate a mean knee Doppler
score. If fluid was aspirated from both knee joints, then both knee
joints were scored independently. The maximum semi-quantita-
tive scores for MCP joints and both wrists (12 joints) were
averaged to produce a ‘‘hand Doppler’’ score.
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Ethical approval was obtained from the Bromley and St
Thomas’ NHS Research Ethics Committees, and all patients and
controls gave written informed consent.
Statistical methods
Values are expressed as mean and standard deviations for
normally distributed data, or median and interquartile range for
non-parametric data. Data were assessed for normality using
D’Agostino & Pearson omnibus normality test. Comparisons
between patients and healthy controls were made using unpaired t
tests or Mann Whitney U tests for parametric and non-parametric
data, respectively. Paired PB/SF or ST samples were analysed
using either paired t or Wilcoxon signed rank matched pairs tests.
Correlation coefficients were obtained using Spearman’s method.
Data were analysed using Prism version 5 (GraphPad Software
Inc, La Jolla, USA). For all tests, p values of less than 0.05 were
considered significant.
Results
Th17 but not Th1 cells are elevated in peripheral blood of
RA patients
We first established whether IL-17, IFNc, or TNFa producing
CD4+ T cells predominate in the PB of established RA patients vs.
age and sex matched healthy controls. PB samples were analysed
from 38 RA patients and 30 healthy control donors (Table 1). 29
patients (76%) were receiving therapy with either DMARDs or
anti-TNF. Of the remaining 9 patients, 4 were DMARD naı ¨ve,
and 5 had discontinued therapy due to adverse events.
Ex vivo (PMA/ionomycin/GolgiStop stimulated for 3 hours)
Th17 cell frequencies were significantly elevated in RA patients vs.
healthy donors (HC median 0.32, inter-quartile range (IQR) 0.21–
0.54%, RA median 0.5, IQR 0.32–1.68%, p=0.005), with a
suggestion of a bimodal distribution (Fig. 1A) in patients. Cells
expressing both IL-17 and IFNc were also observed at significantly
higher frequencies in RA patients. There were no significant
differences in the frequency of Th1 or TNFa-expressing CD4+ T
cells between RA patients and healthy controls, however these
cells were present at higher frequencies than Th17 cells.
Th17, Th1, IL-17+IFNc+ and TNFa expressing CD4+ T cells
are increased at the site of inflammation in RA
To determine whether Th17 cells are also increased at the site
of inflammation, we compared frequencies of Th17, Th1, IL-
17+IFNc+ and TNFa+ CD4+ T cells in SF (22 knees) with paired
PB from 20 patients with active RA. SF was obtained following
PDUS of an inflamed knee joint. Frequencies of Th17 cells were
significantly increased in SF relative to paired PB (Fig. 1B). We
also found highly significant increases in Th1 and IL-17+IFNc+
CD4+ T cells, and an increase in TNFa-producing CD4+ T cells
between the two compartments. Some of this increase may be
explained by an increase in the CD4+ memory T cell fraction in
SF vs. PB; however the mean 6 SD fold increase in Th17 cells
from PB to SF was 6.6 6 12.7 fold (range 0.2–57 fold) whereas the
CD45RO proportion changes two-fold, from 50% in PB to 90–
95% in SF [22] (NG & LT, unpublished data).
IL-17 as well as IFNc producing T cells were also detected in
ST from a small group of patients undergoing arthroscopic biopsy
(Fig. 2). In agreement with data from other groups [12,23], not all
patients had equally high levels of IL-17+ T cells. Interestingly, of
six patients, the four patients with active disease (DAS28.3.2) had
a much higher percentage of IL-17+IFNc- T cells in ST (3–15%)
compared to the two patients that were in remission (DAS28,2.6;
,0.4%). A similar trend was not seen for IFNc producing cells.
These findings suggest a relationship between local IL-17
expression and active synovitis. Of note, in our studies, the vast
majority of cells producing IL-17 in PB, SF or ST were T cells (%
CD3+ mean 6 SD in PB 9564.5; SF 9564.5; ST 95.667.8%,
Fig. 3).
Presence of Th17 cells in synovial fluid is positively
correlated with C-reactive protein and local PDUS score
We then assessed if the presence of CD4+ T cells expressing IL-
17, IFNc or TNFa in SF was correlated with systemic markers of
inflammation (Table 2). The frequency of Th17 cells in SF was
positively correlated with CRP (r=0.51, p=0.04, n=20) whilst no
correlations were observed between systemic markers of inflam-
mation and Th1 cell frequency. Surprisingly, the frequency of
TNFa-producing CD4+ T cells in SF was negatively correlated
with both DAS28 and ESR. In contrast, there were no correlations
between systemic markers of inflammation and inflammatory
cytokine-expressing CD4+ T cells in PB.
PDUS is increasingly used as an imaging biomarker of RA
synovial inflammation, and has been associated with increased
joint damage progression in RA [18,19]. Histopathological studies
suggest association of positive PDUS signal with neoangiogenesis
[24]. However, cytokine expression within the joint has not been
associated with increased PDUS signal thus far. Patients with RA
had ultrasound of either the MCP joints and wrists, or a swollen
knee joint (prior to aspiration of SF). Images were scored semi-
quantitatively on a scale 0–3 as described in the methods
(representative images in Fig. 4). All knee joints had mean
Doppler .0, i.e. all joints scanned had a positive Doppler signal
on at least one image. These patients were all symptomatic with
active disease clinically, requiring joint aspiration. The patients
undergoing hand joint PDUS included a wider cross-section of
disease activity: 4 patients had no active synovitis by PDUS, 7
patients had at least 6 out of 12 joints with positive Doppler. The
remaining patients had up to 5 out of 12 positive joints. Overall,
the mean number of hand joints with positive Doppler (6 SD) was
3.763.1; with an average mean semi-quantitative PDUS score of
0.4760.46. The validity of PDUS as a synovitis biomarker was
confirmed by our findings that PDUS scores of multiple hand
Table 1. Characteristics of patients with RA.
N=38
Age, Mean 6 SD 55.3615.8
Female Sex, n (%) 27 (69)
Disease Duration in years, Median (IQR) 6 (2–10)
Rheumatoid Factor Positive, n (%) 28 (71.8)
Erosive Disease, n (%) 22 (56)
DAS28, Mean 6 SD 4.661.5
ESR, mm/hour, Median (IQR) 20 (11.5–33)
CRP, g/dl, Mean 6 SD 14614.6
DMARDs (excluding anti-TNF), n (%) 18 (47)
Anti-TNFa therapy, n (%) 11 (29)
Systemic steroids, n (%) 8 (21)
Normally distributed data are represented as mean 6 standard deviation,
otherwise as median with inter-quartile range. Mean age of 30 healthy controls
(12 males/18 females) was 51620 years (age and sex not statistically significant
compared to RA group).
doi:10.1371/journal.pone.0012516.t001
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(DAS28, r=0.64, p=0.0005, n=26) and inflammatory markers
(ESR, r=0.54, p=0.005, n=26; CRP r=0.48, p=0.02,
n=24). PDUS of a single knee joint was also positively
correlated with DAS28 (r=0.51, p=0.02), ESR (r=0.48,
p=0.02, both n=26), and CRP (r=0.49, p=0.04, n=24).
When the relationship between PDUS scores and inflammatory
cytokine expressing CD4+ T cell frequencies was investigated, a
positive correlation was observed between SF Th17 cell
frequencies and the local PDUS of the same knee joint
(r=0.61, p=0.002; n=22; Fig. 4B and Table 3). We also found
a positive correlation between knee PDUS and IL-17+IFNc+
CD4+ T cell frequency in SF (r=0.52, p=0.04; n=22). These
relationships were not observed for either Th1 or TNFa
expressing CD4+ T cells in SF, or for Th17, Th1, IL-17+IFNc+
or TNFa-producing CD4+ T cells from PB (Fig. 4B, Table 3).
PDUS data were also available for five patients undergoing ST
biopsies. Patients in remission (n=2, with low levels of IL-17+
cells) had mean PDUS scores of ,1.0, whilst patients with active
disease (n=3) had PDUS.1.5. Together, these data indicate
that PDUS-defined active synovitis is associated with the
presence of local IL-17-producing CD4+ T cells. This finding
provides novel insight into the immunopathological mechanisms
of PDUS-related joint damage progression.
Figure 1. Presence of Th17, Th1, IL-17+IFNc+ and TNFa-expressing CD4+ T cells in RA PB and SF. Mononuclear cells were isolated from
PB from 38 RA patients and 30 healthy controls (A), or paired RA PB and SF samples (n=22) (B). Cells were stimulated ex vivo with PMA and
ionomycin for 3 hours prior to intracellular staining for CD3, CD4, IL-17, IFNc and TNFa. Upper panels in (A, B) show representative gating strategy:
Live cells were gated using forward and side scatter profiles, then CD4+ T cells gated based on their expression of CD3 and CD4, and the intracellular
cytokine expression determined. Lower panels in (A, B) show scatter plots of the percentages of IL-17+IFNc- (Th17 cells), IFNc+IL-17- (Th1 cells), IL-
17+IFNc+ CD4+ T cells and total TNFa+ CD4+ T cells as a percentage of CD4+ T cells. Each symbol/line represents an individual donor. (A) The
percentage of cytokine expressing cells in PB from healthy control vs. RA patients. Horizontal bar represents median value. Comparisons between
groups were made using Mann-Whitney U tests. (B) The percentage of cytokine expressing cells in paired RA PB vs. SF samples. Comparisons were
made using Wilcoxon matched pairs tests.
doi:10.1371/journal.pone.0012516.g001
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VEGF-A production
Angiogenesis is a key process in joint swelling and inflammation
in RA (reviewed in [25]). In our patients, the angiogenic factor
VEGF-A was significantly elevated in SF relative to paired serum
(Fig. 5A, n=15). Since PDUS is a sensitive method of assessing
blood flow within tissues, we found as expected, that knee PDUS
scores correlated strongly with the presence of VEGF-A in SF
(Fig. 5B). In keeping with our observed associations between the
presence of Th17 and IL-17+IFNc+ CD4+ T cells in SF and local
PDUS signal, we found that patients with high frequencies of total
IL-17+ CD4+ T cells in SF (above the median level) had
significantly higher levels of SF VEGF-A. In contrast, there was no
significant difference between SF VEGF-A in patients with high
vs. low IFNc+ CD4+ T cells in SF (Fig. 5C, n=12).
To demonstrate a causal relationship between the presence of
IL-17 producing cells within the joint and VEGF-A production,
we cultured synovial fibroblasts (a known source of VEGF-A [26])
from 6 patients with RA with rIL-17 and measured secreted
VEGF-A (Fig. 5D). As a control for the presence of Th1 or TNFa
producing T cells, we set up parallel experiments with rIFNc and
rTNFa. Some RA synovial fibroblasts spontaneously produced
VEGF-A, however VEGF-A production was significantly in-
creased by rIL-17 even at low concentrations (1 ng/ml). rIL-17 at
higher concentrations also significantly induced IL-6 secretion by
RA synovial fibroblasts, a cytokine involved in both inflammation
and angiogenesis (reviewed in [27]). Similar increases in VEGF-A
production were seen upon addition of rTNFa. No evidence was
observed for synergy between rTNFa and rIL-17 (Fig. 5E).
Addition of rIFNc did not induce VEGF-A or IL-6 secretion, and
in fact reduced VEGF-A levels and IL-6 in 4 out of 6 fibroblast
lines. Given that IL-17, TNFa as well as IFNc producing T cells
are simultaneously present in the RA joint (Fig. 1, 2), we assessed
the effect of the combined cytokines on VEGF-A and IL-6
production. In all three lines tested, a clear increase in VEGF-A as
well as IL-6 was observed (Fig. 5E), indicating that the potentially
antagonistic effect of rIFNc was overcome by rIL-17 and rTNFa.
Together, these data are highly suggestive of a role of local IL-17
in stimulating VEGF-A production and angiogenesis.
Discussion
In this paper, we demonstrate that Th17, Th1 and IL-
17+IFNc+ CD4+ T cells as well as TNFa-expressing CD4+ T
cells are enriched within RA SF relative to paired PB. The
frequency of Th17 cells in SF correlates significantly with CRP, a
marker for systemic inflammation, suggesting that local Th17 cells
contribute to active disease. In contrast, although Th1 cells greatly
outnumbered IL-17+ T cells in SF, they did not correlate with
markers of inflammation. These data support the DAMAGE
study, which showed that synovial tissue IL-17 mRNA levels
strongly correlate with CRP, and in synergy with TNFa, predict
rapid joint damage progression in RA [23]. Importantly, we also
detected IL-17+ T cells in ST, but only at significant levels in those
patients that had active RA, suggesting that IL-17+ T cell numbers
may vary with disease activity (Fig. 2). Other studies also report
that IL-17+ T cells or IL-17 mRNA are not universally present in
RA ST, and are found in 28–60% of RA ST samples [12,23,28]. A
recent paper reported that mast cells rather than T cells are the
major source of IL-17 in RA ST [29]. In our experiments the vast
majority of cells in PB, SF and ST producing IL-17 were T cells,
although our protocol used T cell stimulation with PMA and
ionomycin. In addition, Stamp et al did not detect IL-17
production by other cell types [12]. One explanation for these
different observations may be that in the study by Hueber et al.S T
was obtained at the time of joint replacement, where tissue
responses to joint damage may predominate over active
inflammation. Indeed, high levels of mast cells are observed in
avascular, fibrotic regions of RA synovial tissue, without
correlations with lymphocytic infiltration [30].
Both synovial tissue IL-17 mRNA expression and persistent
PDUS signal have been independently associated with increased
joint damage progression in RA [18,19,23]. Histopathological
studies suggest association of positive PDUS signal with neoangio-
genesis [24]. However cytokine expression within the joint has not
Figure 2. IFNc and IL-17-producing T cells are increased in synovial tissue from patients with active RA. Mononuclear cells were isolated
from PB. Synovial tissue (ST) samples were obtained at arthroscopic synovial biopsy and digested with collagenase prior to stimulation and staining
as described in Fig. 1. Stains for TNFa were not performed. A) T cells were gated based on CD3 expression, and intracellular cytokine expression
determined. B) Scatter plots of PB vs. ST, showing percentages of IL-17+IFNc-, IFNc+IL-17-, IL-17+IFNc+ and total IL-17+ T cells as a percentage of
CD3+ T cells (n=6). Closed symbols: patients with active disease (DAS28.3.2); open symbols: patients in remission (DAS28,2.6).
doi:10.1371/journal.pone.0012516.g002
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PLoS ONE | www.plosone.org 5 September 2010 | Volume 5 | Issue 9 | e12516Figure 3. IL-17+ cells from RA PB, SF and ST are predominantly CD3+ T cells. A) PB (n=18), SF (n=10) and ST (n=6)-derived cells were
prepared as described in the Methods, and live cells were gated using forward and side scatter profiles. IL-17+ cells were identified based on isotype
control staining, and the percentage of either CD3+ or CD3+CD4+ T cells within the IL-17+ gate determined for each sample. B) Bar graphs showing
mean and SD of the percentage CD4+ T cells within the IL-17+ population for PB and SF, and of the percentage CD3+ T cells within the IL-17+
population for PB, SF and ST.
doi:10.1371/journal.pone.0012516.g003
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demonstration that the local presence of IL-17 producing CD4+
T cells (either Th17 or IL-17+IFNc+ T cells) in the RA joint is
associated with active synovitis measured by PDUS, provides
novel mechanistic insight into PDUS-related immunopathology.
Through their production of IL-17 and TNFa, Th17 cells can
promote osteoclastogenesis [31] and cartilage damage [32,33] in
the RA joint, thus accelerating joint damage progression. In
addition, we demonstrate that IL-17 and TNFa promote VEGF-A
production by RA synovial fibroblasts. A role for IL-17 in
angiogenesis is supported by the recent findings that local
overexpression of IL-17 in C57BL/6 mice induces arthritis with
increased vascularity, and that IL-17 induces migration of
endothelial cells in vitro, along with increased angiogenesis in
Matrigel plugs [34]. In contrast, we found that IFNc did not
induce VEGF-A secretion by RA synovial fibroblasts, which is in
agreement with the lack of correlation between local Th1 cell
frequency and PDUS signal. The lack of correlation with IFNc is
in agreement with the findings that IFNc mRNA levels in ST were
strongly negatively correlated with joint damage progression [23],
and that Th1 cells inhibit development of osteoclasts [31].
Highly vascularized synovium (indicated by positive PDUS
signal) is likely to permit increased influx of inflammatory cells into
the joint, and one explanation for our findings could therefore be
that Th17 cells are elevated simply as a bystander effect. However,
the lack of correlation between the frequency of Th1 cells or
TNFa+ CD4+ T cells with PDUS scores argues against this
explanation. In contrast to non-specific influx, Th17 cells may
preferentially migrate into the joint via CCR6 interaction with
CCL20, which is strongly expressed in the synovium [35]. In
addition, we have previously proposed a mechanism for
generation of Th17 cells in the joint itself, as cell contact with
in vitro (LPS) activated [36] or in vivo activated monocytes from
inflamed joints from RA patients [11] leads to induction of IL-17
production in memory CD4+ T cells, suggesting that newly
Table 2. Correlations between frequencies of Th17, Th1, IL-
17+IFNc+ and TNFa expressing CD4+ T cells in synovial fluid
and peripheral blood and DAS28, ESR and CRP.
DAS28 ESR CRP
SF (n=22) r p r p r p
Th17 0.16 0.49 0.27 0.49 0.51 0.04
Th1 20.21 0.34 20.36 0.34 20.16 0.84
IL-17+IFNc+ 0.06 0.79 0.08 0.76 0.31 0.28
CD4+ TNFa (n=18) 20.70 0.002 20.65 0.008 20.48 0.10
PB (n=38)
Th17 0.10 0.53 20.14 0.40 0.07 0.70
Th1 0.08 0.63 20.13 0.46 0.06 0.73
IL-17+IFNc+ 0.10 0.56 20.16 0.34 20.12 0.51
CD4+ TNFa (n=32) 20.13 0.5 20.1 0.6 20.21 0.29
Correlations were performed using Spearman’s rank correlation. Statistically
significant correlations are indicated in bold.
doi:10.1371/journal.pone.0012516.t002
Figure 4. Single knee PDUS scores are highly correlated with the presence of Th17 cells in SF. A) Representative images for semi-
quantitative ultrasound scoring (MCP, upper panel; knee, lower panel). B) Correlations between knee PDUS scores and the percentage of Th17 cells in
SF vs. PB (n=22). The regression lines with 95% confidence intervals are shown.
doi:10.1371/journal.pone.0012516.g004
PDUS Links to Th17 Cells in RA
PLoS ONE | www.plosone.org 7 September 2010 | Volume 5 | Issue 9 | e12516recruited CD4+ T cells can be skewed toward a Th17 phenotype
at the site of inflammation.
Despite the fact that we found significant increases in Th17 and
IL-17+IFNc+ CD4+ T cells in the blood of RA patients vs. healthy
donors, these subsets did not correlate with markers of disease such
as ESR, CRP or DAS28. This suggests that the presence of IL-17
producing CD4+ T cells in the blood from patients with
established RA is of limited use as a biomarker to indicate disease
activity. A significant increase in the percentage of IL-17+ CD4+
T cells in PB of RA patients vs. healthy donors was recently also
described by Shen et al. [37]. In contrast, two separate studies
reported no differences in Th17 cell frequency in PB of RA
patients vs. healthy controls [28,38]. All three studies, however,
concur with ours that no differences are detected in the percentage
of Th1 cells in RA vs. healthy donors. It is currently unclear why
the observations regarding Th17 cell frequencies in RA are more
varied, but this may be due in part to different demographics and
treatment regimes in the patient populations. Indeed, it is worth
noting that in all these studies the focus has been on RA patients
with established disease, treated with a wide variety of therapies,
which in combination with changes in disease activity could
influence PB Th17 levels and their correlations with markers of
disease activity. This idea is supported by a recent study involving
patients with early, treatment-naive RA and psoriatic arthritis
where systemic disease activity in the early disease stages strongly
correlated with the frequency of Th17 cells within PB [39].
Our finding that TNFa expressing CD4+ T cells in SF were
negatively correlated with DAS28 and ESR is perhaps surprising
given the well-documented responses to TNFa antagonists in RA
[40,41,42]. However, we analysed expression of TNFa by CD4+
T cells only, whilst TNFa is expressed by many other cells in
rheumatoid synovium, in particular cells of the monocyte-
macrophage lineage [43]. There are few studies documenting
the relationship between disease activity and expression of TNFa
in the joint, and these studies have used TNFa expression in
synovial tissue. Tak et al showed a strong correlation between semi-
quantitative histology scores for TNFa and knee pain but no
correlations were reported for either systemic inflammatory
markers or global disease activity [44]. Morand et al found no
correlations between synovial lining layer TNFa and measures of
disease activity, but noted reduced TNFa following successful
therapy with DMARDs [45]. Clearly further research relating
markers of disease activity to TNFa ˜expression in T cells vs.
monocytes/macrophages and fibroblasts from synovial fluid vs.
tissue is still required.
Limitations
We defined Th17 and Th1 cells on the basis of cytokine
expression by CD4+ T cells rather than presence or absence of
specific transcription factors such as RORc2 or T-bet. Although
this approach is widely used in the field (e.g. [28,39,46,47]), one
should remain aware that our study describes specific cytokine
profiles of CD4+ T cells rather than cell lineage.
As we aimed to obtain ST from arthroscopic biopsies rather
than from patients undergoing joint replacement to prevent
confounding by fibrotic tissue findings, only a relatively low
number of synovial tissue samples were available to investigate if
remission is associated with low levels of IL-17+ T cells. One
possibility could have been to extend the dataset with SF data,
however all of our patients requiring SF aspiration had active
disease. Interestingly though, patients with low disease activity
(DAS28,3.2) had significantly lower Th17 cells in SF than
patients with active disease (DAS28.3.2) (median 1.5 vs. 0.35%,
p=0.04, n=22, data not shown), lending further weight to the
associations between systemic inflammation, local synovitis and
Th17 cell frequency.
Our data raise a number of other questions regarding the
presence of Th17 cells in RA. We have observed a relationship
between local, but not peripheral blood Th17 cells and active
synovitis. This relationship may be more pronounced at earlier
stages of disease, with IL-17 having a greater contribution towards
joint damage progression [23]. It is now clear that some
experimental arthritis models are dependent on Th1/IFNc [48],
whilst others are Th17/IL-17 dependent [49] or switch from
TNFa dependency to a Th17/IL-17 profile in later stages of
disease [50]. This raises the possibility that in RA T helper cell
subsets may play different roles at different stages of disease or
depending on genetic background of patients, which may affect
disease activity or outcome.
Furthermore, in a cross-sectional study such as ours, we are
unable to conclude if the relationship with active disease activity is
dynamic; i.e. are Th17 cells present at times of active disease and
disappear when disease is suppressed? In addition, it is intriguing
to speculate if the presence of these cells specifically indicates those
patients with a predominantly IL-17/Th17-mediated disease from
the outset and who may thus benefit from specific therapy with IL-
17 antagonists. Interestingly, a number of the patients in this study
with high levels of Th17 cells in SF were non-responders to anti-
TNF therapy, and this could either indicate that these patients
have IL-17-related pathology, or that the presence of Th17 cells in
the joint is a marker of poor response to TNFa blockade.
Longitudinal studies including ST biopsies before and after IL-17
vs. TNFa antagonists will be required to answer these important
questions.
In summary, we have used PDUS as a biomarker of active
synovitis to explore relationships between imaging and T cell-
mediated immunopathology. This technique could be replicated
to investigate contributions of other cell types including mono-
cytes/macrophages to immunopathology in RA. PDUS is
increasingly used to identify patients at risk of joint damage
progression in the clinic. Our data provide an immunologic
explanation for this clinical observation by demonstrating that the
presence of the pro-inflammatory and osteoclastogenic Th17 cell
subset in the inflamed joint strongly correlates with both disease
Table 3. Correlations between local knee PDUS score and
frequencies of Th17, Th1, IL-17+IFNc+ and TNFa expressing
CD4+ T cells in SF vs. PB.
Knee PDUS score
Spearman correlation (n=22)
SF rp
Th17 0.61 0.002
Th1 20.04 0.61
IL-17+IFNc+ 0.52 0.04
CD4+ TNFa (n=18) 20.14 0.59
PB
Th17 0.12 0.57
Th1 20.03 0.91
IL-17+IFNc+ 20.08 0.69
CD4+ TNFa (n=18) 0.20 0.43
Correlations were performed using Spearman’s rank correlations. Statistically
significant correlations are indicated in bold.
doi:10.1371/journal.pone.0012516.t003
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PLoS ONE | www.plosone.org 9 September 2010 | Volume 5 | Issue 9 | e12516activity and local PDUS score in RA. Our findings thus highlight
PDUS as a possible surrogate marker of Th17 cells, and may
identify patients who would benefit from early, aggressive therapy,
including IL-17 antagonists.
Acknowledgments
We are grateful to Prof Chris Buckley and Dr Karim Raza (University of
Birmingham) for assistance with study design and review of the manuscript.
Author Contributions
Conceived and designed the experiments: NJG HGE AF BK LST.
Performed the experiments: NJG HGE LDC DMJ. Analyzed the data:
NJG HGE. Contributed reagents/materials/analysis tools: AF LST. Wrote
the paper: NJG HGE LDC AF BK LST.
References
1. McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid
arthritis. Nat Rev Immunol 7: 429–422.
2. Cope A (2008) T cells in rheumatoid arthritis. Arthritis Res Ther 10: S1.
3. Lubberts E, Koenders MI, van den Berg WB (2005) The role of T-cell
interleukin-17 in conducting destructive arthritis: lessons from animal models.
Arthritis Res Ther 7: 29–37.
4. Chabaud M, Fossiez F, Taupin JL, Miossec P (1998) Enhancing effect of IL-17
on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid
arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 161:
409–414.
5. Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, et al. (2000)
Contribution of interleukin 17 to synovium matrix destruction in rheumatoid
arthritis. Cytokine 12: 1092–1099.
6. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, et al.
(1998) IL-17 stimulates the production and expression of proinflammatory
cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 160:
3513–3521.
7. Ruddy MJ, Shen F, Smith JB, Sharma A, Gaffen SL (2004) Interleukin-17
regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts:
implications for inflammation and neutrophil recruitment. J Leuk Biol 76:
135–144.
8. Shahrara S, Pickens SR, Dorfleutner A, Pope RM (2009) IL-17 induces
monocyte migration in rheumatoid arthritis. J Immunol 182: 3884–3891.
9. Sato K (2008) Th17 cells and rheumatoid arthritis—from the standpoint of
osteoclast differentiation. Allergol Int 57: 109–114.
10. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, et al. (1999) Human
interleukin-17: A T cell-derived proinflammatory cytokine produced by the
rheumatoid synovium. Arthritis Rheum 42: 963–970.
11. Evans HG, Gullick NJ, Kelly S, Pitzalis C, Lord GM, et al. (2009) In vivo
activated monocytes from the site of inflammation in humans specifically
promote Th17 responses. Proc Natl Acad Sci USA 106: 6232–6237.
12. Stamp LK, Easson A, Petterson L, Highton J, Hessian PA (2009) Monocyte
Derived Interleukin (IL)-23 Is an Important Determinant of Synovial IL-17A
Expression in Rheumatoid Arthritis. J Rheumatol 36: 2403–2408.
13. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee C-Y, et al. (2005) Early
rheumatoid arthritis is characterized by a distinct and transient synovial fluid
cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 7:
R784–795.
14. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, et al.
(2010) LY2439821, a Humanized Anti-IL-17 Monoclonal Antibody, in the
Treatment of Patients with Rheumatoid Arthritis: A Phase 1 Randomized,
Double-Blind, Placebo-Controlled, Proof of Concept Study. Arthritis Rheum 62:
929–939.
15. Skapenko A, Prots I, Schulze-Koops H (2009) Prognostic factors in rheumatoid
arthritis in the era of biologic agents. Nat Rev Rheumatol 5: 491–496.
16. McDicken WN, Anderson T (2002) The Difference Between Colour Doppler
Velocity Imaging and Power Doppler Imaging. Eur J Echocardiography 3:
240–244.
17. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, et al. (2006)
Presence of significant synovitis in rheumatoid arthritis patients with disease-
modifying antirheumatic drug-induced clinical remission: evidence from an
imaging study may explain structural progression. Arthritis Rheum 54:
3761–3773.
18. Naredo E, Collado P, Cruz A, Palop MJ, Cabero F, et al. (2007) Longitudinal
power Doppler ultrasonographic assessment of joint inflammatory activity in
early rheumatoid arthritis: predictive value in disease activity and radiologic
progression. Arthritis Rheum 57: 116–124.
19. Taylor PC, Steuer A, Gruber J, McClinton C, Cosgrove DO, et al. (2006)
Ultrasonographic and radiographic results from a two-year controlled trial of
immediate or one-year-delayed addition of infliximab to ongoing methotrexate
therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum 54:
47–53.
20. Naredo E, Moller I, Cruz A, Carmona L, Garrido J (2008) Power Doppler
ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in
patients with rheumatoid arthritis. Arthritis Rheum 58: 2248–2256.
21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. (1988) The
American Rheumatism Association 1987 revised criteria for the classification of
rheumatoid arthritis. Arthritis Rheum 31: 315–324.
22. Verwilghen J, Corrigall V, Pope RM, Rodrigues R, Panayi GS (1993)
Expression and function of CD5 and CD28 in patients with rheumatoid
arthritis. Immunology 80: 96–102.
23. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, et al. (2006)
Synovial membrane cytokine expression is predictive of joint damage
progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE
study cohort). Arthritis Rheum 54: 1122–1131.
24. Walther M, Harms H, Krenn V, Radke S, Faehndrich TP, et al. (2001)
Correlation of power Doppler sonography with vascularity of the synovial tissue
of the knee joint in patients with osteoarthritis and rheumatoid arthritis. Arthritis
Rheum 44: 331–338.
25. Paleolog EM (2002) Angiogenesis in rheumatoid arthritis. Arthritis Res 4 Suppl
3: S81–90.
26. Ryu S, Lee JH, Kim SI (2006) IL-17 increased the production of vascular
endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol
25: 16–20.
27. Nishimoto N (2006) Interleukin-6 in rheumatoid arthritis. Curr Op Rheumatol
18: 277–281.
28. Yamada H, Nakashima Y, Okazaki K, Mawatari T, Fukushi JI, et al. (2008) Th1
but not Th17 cells predominate in the joints of patients with rheumatoid
arthritis. Ann Rheum Dis 67: 1299–1304.
29. Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, et al. (2010) Cutting Edge:
Mast Cells Express IL-17A in Rheumatoid Arthritis Synovium. J Immunol 184:
336–340.
30. Gotis-Graham I, McNeil HP (1997) Mast cell responses in rheumatoid
synovium. Association of the MC-TC subset with matrix turnover and clinical
progression. Arthritis Rheum 40: 479–489.
31. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, et al. (2006)
Th17 functions as an osteoclastogenic helper T cell subset that links T cell
activation and bone destruction. J Exp Med 203: 2673–2682.
32. van Roon JA, Van Roy JL, Duits A, Lafeber FP, Bijlsma JW (1995)
Proinflammatory cytokine production and cartilage damage due to rheumatoid
synovial T helper-1 activation is inhibited by IL-4. Ann Rheum Dis 54:
836–840.
33. Wilbrink B, Nietfeld JJ, Den Otter W, Van Roy JLAM, Bijlsma JWJ, et al. (1991)
Role of TNF alpha, in relation to IL-1 and IL-6 in the proteoglycan turnover of
human articular cartilage. Br J Rheumatol 30: 265–271.
34. Pickens SR, Volin MV, Mandelin AM, 2nd, Kolls JK, Pope RM, et al. (2010)
IL-17 contributes to angiogenesis in Rheumatoid Arthritis. J Immunol: 3233–
3241.
35. Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, et al. (2007)
Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via
CCL20 in rheumatoid arthritis and its animal model. J Exp Med 204:
2803–2812.
36. Evans HG, Suddason T, Jackson I, Taams LS, Lord GM (2007) Optimal
induction of T helper 17 cells in humans requires T cell receptor ligation in the
Figure 5. The presence of Th17 cells in SF is linked to increased VEGF in SF. A) VEGF-A levels in cell-free RA SF and matched paired serum
were determined by ELISA (n=15). B) Scatter plot of VEGF-A levels in SF vs. knee PDUS score, and the corresponding Spearman correlation coefficient
and p-values. The regression line and 95% confidence intervals are shown. C) SF VEGF-A levels in RA patients stratified based on their frequency of
total IL-17+ CD4+ T cells or total IFNc+ CD4+ T cells (below or above the median level). Groups were compared using Mann Whitney U tests. (n=12)
D) RA synovial fibroblasts (n=6) were cultured for 48 hours in the presence of 1 ng/ml rIL-17, 10 ng/ml rIL-17, 10 ng/ml rTNFa or 10 ng/ml rIFNc.
VEGF-A and IL-6 were measured in culture supernatants by ELISA. Comparison between groups was made using one-way ANOVA; * p,0.05. E) RA
synovial fibroblasts (n=3) were cultured for 48 hours alone or with a combination of 1 ng/ml rIL-17, 10 ng/ml rTNFa, and 10 ng/ml rIFNc prior to
measurement of VEGF-A and IL-6 in supernatants.
doi:10.1371/journal.pone.0012516.g005
PDUS Links to Th17 Cells in RA
PLoS ONE | www.plosone.org 10 September 2010 | Volume 5 | Issue 9 | e12516context of Toll-like receptor-activated monocytes. Proc Natl Acad Sci USA 104:
17034–17039.
37. Shen H, Goodall JC, Gaston JSH (2009) Frequency and phenotype of peripheral
blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis
Rheum 60: 1647–1656.
38. Jandus C, Bioley G, Rivals J-P, Dudler J, Speiser D, et al. (2008) Increased
numbers of circulating polyfunctional Th17 memory cells in patients with
seronegative spondylarthritides. Arthritis Rheum 58: 2307–2317.
39. Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, et al. (2010) Th17 cells
in autoimmune arthritis. Arthritis Rheum: http://dx.doi.org/10.1002/art.
27622.
40. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, et al. (1999) Infliximab
(chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo
in rheumatoid arthritis patients receiving concomitant methotrexate: a
randomised phase III trial. ATTRACT Study Group. Lancet 354: 1932–1939.
41. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, et al.
(2002) Etanercept versus methotrexate in patients with early rheumatoid
arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46:
1443–1450.
42. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, et al. (2004)
Radiographic, Clinical, and Functional Outcomes of Treatment with Adalimu-
mab (a Human Anti-Tumor Necrosis Factor Monoclonal Antibody) in Patients
with Active Rheumatoid Arthritis Receiving Concomitant Methotrexate
Therapy: A Randomized, Placebo-Controlled, 52-Week Trial. Arthritis Rheum
50: 1400–1411.
43. Chu CQ, Field M, Feldmann M, Maini RN (1991) Localization of Tumor
Necrosis Factor alpha in Synovial Tissues and at the Cartilage-Pannus Junction
in Patients With Rheumatoid Arthritis. Arthritis Rheum 34: 1125–1132.
44. Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers K, et al. (1997) Analysis of
the synovial infiltrate in early rheumatoid tissue in relation to local disease
activity. Arthritis Rheum 40: 217–225.
45. Morand EF, Leech M, Weedon H, Metz C, Bucala R, et al. (2002) Macrophage
migration inhibitory factor in rheumatoid arthritis: clinical correlations.
Rheumatology (Oxford) 41: 558–562.
46. Chen Z, Tato CM, Muul L, Laurence A, O’Shea JJ (2007) Distinct regulation of
interleukin-17 in human T helper lymphocytes. Arthritis Rheum 56: 2936
–2946.
47. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, et al. (2007)
Phenotypic and functional features of human Th17 cells. J Exp Med 204:
1849–1861.
48. Doodes PD, Cao Y, Hamel KM, Wang Y, Farkas B, et al. (2008) Development
of proteoglycan induced arthritis is independent of IL-17. J Immunol 181: 329 -
337.
49. Nakae S, Saijo S, Horai R, Sudo K, Mori S, et al. (2003) IL-17 production from
activated T cells is required for the spontaneous development of destructive
arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA
100: 5986–5990.
50. Koenders MI, Lubberts E, van de Loo FAJ, Oppers-Walgreen B, van den
Bersselaar L, et al. (2006) Interleukin-17 acts independently of TNF-alpha under
arthritic conditions. J Immunol 176: 6262–6269.
PDUS Links to Th17 Cells in RA
PLoS ONE | www.plosone.org 11 September 2010 | Volume 5 | Issue 9 | e12516